Conventional and Alternative Pain Treatment Markets

Report Highlights

The global market for conventional and alternative pain treatment is expected to grow from $96.2 billion in 2024 and is projected to reach $144.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.4% during the forecast period of 2024 to 2029.

Report Includes

• 48 data tables and 56 additional tables
• Analysis of the global market for conventional and alternative pain treatments
• Analyses of global market trends, with market revenue data from 2012-2023, estimates for 2024, and projected CAGRs through 2029
• Estimate of the current market size and revenue prospects of the global market, along with a market share analysis by pain management type, application and region
• Facts and figures pertaining to the market dynamics, technological advances, regulations, and the influence of macroeconomic factors
• A Porter’s Five Forces analysis, a global supply chain analysis and a SWOT analysis
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, ESG score analysis, and the ESG practices of leading companies
• A look at recent patent grants
• Analysis of the industry structure and competitive landscape, including company market shares, strategic alliances, M&A activity and venture funding outlook
• Profiles of market leaders, including Medtronic, Abbott, GSK, Pfizer Inc., and Johnson & Johnson

Report Scope

This report covers the conventional and alternative pain treatments used by patients with chronic or acute pain. It provides the current and future market potential of conventional and alternative pain treatments and includes a detailed analysis of the competitive environment. The report covers the drivers, restraints and opportunities in the market; surveys the prevalence of or incidence of chronic diseases; and highlights emerging technologies for alternative treatment procedures. It includes market projections for 2029 and provides the market shares of key players.

In this analysis, the conventional and alternative pain treatment market is segmented based on pain management type into pharmaceuticals/drug therapy and devices. The pharmaceuticals/drug therapy segment is further segmented into non-narcotic analgesics, medical cannabis, narcotic analgesics, antimigraine agents, central nervous system (CNS) treatments, anesthetics, and other classes of pharmaceutical drug therapy. The devices segment of the conventional and alternative pain treatment market is further segmented into spine stimulators, electrotherapy/muscle stimulation, and other devices. Based on application, the overall conventional and alternative pain treatment market is segmented into orthopedic and musculoskeletal pain, general and broad pain management, surgical pain management, migraine/headache pain, neuropathic pain, cancer pain, fibromyalgia pain, and other pain types.

The overall conventional and alternative pain treatment market has also been segmented by geography into North America, Europe, Asia-Pacific, Latin America and Middle East & Africa (MEA). Each regional analysis covers the region’s leading countries, namely, the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico and GCC countries. Market data is provided for 2023, which serves as the base year; estimates are given for 2024 and forecast values for 2029.

Analyst Credentials

Partha Sarathi Das– Associate Consultant-Life Science Research
Partha Sarathi has an experience of nearly a decade in multiple domains, including healthcare, life science, biotechnology, pharmaceuticals, and healthcare IT. His expertise is in designing research studies, gathering data, and performing analysis, ultimately providing clients with actionable insights and recommendations based on their unique business needs. Designs proposal and participates in client queries for quick delivery based on their unique business needs. Academically, Parthasarathi holds a master’s degree in Biotechnology and a bachelor’s degree in Industrial Biotechnology.

Consulting Editor’s Credentials

Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology, assay development, antibody and drug manufacturing. She has authored several scientific publications in peer review journals. In the last 10 years, Marianna worked as a business development professional in CRO/CDMO industry. She is familiar with pharmaceutical and biotech landscape, trends and potential future developments in industry.